Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1994-2-17
|
pubmed:abstractText |
Early development of immunity after hepatitis B vaccination is particularly important for patients such as hemophiliacs, at high risk for acquiring hepatitis B from potentially infectious plasma-derived concentrates. The purpose of this study was to evaluate whether or not protective antibody titers could be achieved quickly and maintained in hemophiliacs by an accelerated vaccination schedule. A yeast-recombinant hepatitis B vaccine (Engerix B, SKF Ritt) was given subcutaneously in the deltoid region and repeated 2 and 6 weeks later to 85 hemophiliacs negative for hepatitis B virus (HBV) markers. After the first 22 patients had been enrolled, a modification of the schedule involving a fourth booster dose 24 weeks after the first dose of vaccine was applied to the next 63 consecutive vaccines. Fifty-three percent of vaccinees had antibody titers to hepatitis B surface antigen (anti-HBs > or = 10 mlU/ml) by week 6, even though the mean titers of anti-HBs were somewhat lower than those achieved historically in normal individuals. The protection rate had increased to 87% by week 10, one month after the third dose of vaccine, and to 93% by week 24. One year after starting vaccination, the rate for the vaccinees who did not receive the fourth booster dose was 71%, and 96% for those who did receive the fourth dose, with only 2 patients not responding despite the booster dose. It is concluded that even though the accelerated schedule of immunization produced rapidly high rates of protective antibody titers, a booster dose is required to obtain higher titers and provide more persistent immunity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0146-6615
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
41
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
95-8
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8283182-Adolescent,
pubmed-meshheading:8283182-Adult,
pubmed-meshheading:8283182-Aged,
pubmed-meshheading:8283182-Aged, 80 and over,
pubmed-meshheading:8283182-Child,
pubmed-meshheading:8283182-Child, Preschool,
pubmed-meshheading:8283182-Female,
pubmed-meshheading:8283182-Hemophilia A,
pubmed-meshheading:8283182-Hepatitis B Antibodies,
pubmed-meshheading:8283182-Hepatitis B Vaccines,
pubmed-meshheading:8283182-Humans,
pubmed-meshheading:8283182-Infant,
pubmed-meshheading:8283182-Male,
pubmed-meshheading:8283182-Middle Aged,
pubmed-meshheading:8283182-Time Factors
|
pubmed:year |
1993
|
pubmed:articleTitle |
Accelerated schedule of hepatitis B vaccination in patients with hemophilia.
|
pubmed:affiliation |
Study Group of the Fondazione dell'Emofilia, Milan, Italy.
|
pubmed:publicationType |
Journal Article
|